CDH2-Related ACOG Syndrome: Comprehensive Research Report

Executive Summary

CDH2-related ACOG syndrome (Agenesis of Corpus Callosum, Ocular, Cardiac, and Genital syndrome; also referred to in OMIM as ACOGS) is an ultra-rare, autosomal dominant, multisystem neurodevelopmental disorder caused by de novo heterozygous pathogenic variants in CDH2, the gene encoding N-cadherin (neuronal cadherin). It was first delineated as a distinct Mendelian syndrome in 2019 by Accogli, Srour, Charron, and colleagues (PMID:31585109), who proposed the name "ACOG syndrome" for the pentad of axon-pathfinding defects, corpus callosum anomalies, and ocular, cardiac, and genital malformations. As of the most recent case series (2022), only ~15 individuals have been reported worldwide (PMID:35708058), making this one of the rarest entries in the cadherinopathy spectrum.

1. Disease Information

Overview: CDH2-related ACOG syndrome is a syndromic neurodevelopmental disorder resulting from de novo heterozygous loss-of-function or dominant-negative missense variants in CDH2. The disorder was defined by Accogli et al. (2019), who identified nine individuals with de novo CDH2 variants (seven missense, two frameshift) presenting with "global developmental delay and/or intellectual disability, variable axon pathfinding defects (corpus callosum agenesis or hypoplasia, mirror movements, Duane anomaly), and ocular, cardiac, and genital anomalies" (PMID:31585109). The authors coined the acronym "ACOG syndrome" — Agenesis of corpus callosum, axon pathfinding, Cardiac, Ocular, and Genital defects.

A related, overlapping presentation with a prominent anterior-segment eye phenotype was independently reported as "a new syndrome including Peters anomaly" caused by CDH2 variants (Peters Anomaly Spectrum group, PMID:31650526, Clinical Genetics 2020;97(3):502-508), describing four individuals with de novo CDH2 variants (splicing + missense) and Peters anomaly, three of whom had syndromic features overlapping ACOG syndrome (agenesis of the corpus callosum, cerebellar vermis hypoplasia, left-sided cardiac lesions, dysmorphic facies). These two reports are now generally regarded as describing the same CDH2-related disorder spectrum.

Key identifiers: - OMIM (phenotype): #618929 — "Agenesis of Corpus Callosum, Cardiac, Ocular, and Genital Syndrome; ACOGS" - OMIM (gene): 114020 — CADHERIN 2; CDH2 - MONDO: MONDO:0030065 - Disease Ontology: DOID:0080948 - NCBI GTR condition: C5394523 - Gene identifiers: HGNC:1759; NCBI Gene ID: 1000; chromosome 18q12.1 - ICD-10/11: No dedicated ICD code exists; typically coded under Q04.0 (agenesis of corpus callosum) or Q89.7 (multiple congenital malformations, not elsewhere classified) in practice — no CDH2-specific ICD-11 entry was identified. - MeSH:* No dedicated MeSH heading; indexed under "Agenesis of Corpus Callosum" (D019112) and "Cadherins" (D029464).

Synonyms: ACOGS; ACOG syndrome; CDH2-related neurodevelopmental disorder; "N-cadherinopathy"; the Peters-anomaly-predominant presentation is sometimes referenced separately as "CDH2-related Peters anomaly syndrome."

Evidence base: All currently published information derives from aggregated case series/case reports (human clinical, aggregated across ~15 patients total in the two founding cohorts plus subsequent single case reports) rather than large-scale EHR data, reflecting the extreme rarity of the condition.

2. Etiology

Disease causal factors: ACOG syndrome is caused exclusively by de novo heterozygous pathogenic variants in CDH2 (autosomal dominant, essentially 100% de novo in reported cases). No environmental, infectious, or multifactorial causes have been implicated; this is a purely monogenic disorder.

Genetic risk factors: - All reported pathogenic variants are heterozygous and arose de novo — no inherited/familial transmission has been documented, consistent with a severe, likely-reproductively-limiting phenotype. - Variant spectrum from the founding cohort: seven missense variants and two frameshift variants (PMID:31585109). "Six of the seven missense variants localize to extracellular cadherin domains 4–5 (EC4–EC5), with four affecting calcium-binding sites" — functional studies showed these EC4–EC5 variants impair cell-cell adhesion. - The Peters-anomaly cohort (PMID:31650526) added a de novo splicing variant and additional missense variants in the extracellular cadherin domains. - ClinVar-documented variants associated with ACOGS include NM_001792.5(CDH2):c.1057G>A (p.Asp353Asn), c.1808C>G (p.Pro603Arg), and c.2027A>G (p.Tyr676Cys), among others. - The Kanjee et al. (2022) case (PMID:35708058) reported a novel de novo nonsense variant, expanding the mutational mechanism beyond missense/frameshift to include premature-stop-codon variants.

Modifier/susceptibility factors: No modifier genes have been identified; given the extremely small number of reported cases, genotype-phenotype correlation is preliminary. Variants clustering in EC4–EC5 appear to correlate with the more classic ACOG presentation (CNS/axon-pathfinding-predominant), while some variants correlate more with the Peters-anomaly/anterior-segment ocular phenotype, but sample sizes are too small for robust correlation.

Protective factors: None identified — no protective genetic or environmental factors have been reported for this ultra-rare monogenic disorder.

Gene-environment interactions: None reported; the disorder behaves as a fully penetrant (or near-fully penetrant), single-gene Mendelian condition with no documented environmental modifiers.

3. Phenotypes

Phenotype frequencies below are drawn from the aggregated cohort of the two founding reports (approximately 9–13 evaluable individuals per feature; PMID:31585109, PMID:31650526) plus subsequent case reports (PMID:35708058).

Neurodevelopmental / Neurological

Global developmental delay / intellectual disability — reported in ~10/12 evaluable patients; variable severity (mild–moderate most common). Suggested HPO: HP:0001263 (Global developmental delay), HP:0001249 (Intellectual disability)
Agenesis or hypoplasia of the corpus callosum — reported in ~11/13; the defining CNS feature, reflecting failure of interhemispheric axon pathfinding. Suggested HPO: HP:0001274 (Agenesis of corpus callosum), HP:0002079 (Hypoplasia of the corpus callosum)
Cerebellar vermis hypoplasia — described in both cohorts. Suggested HPO: HP:0001320 (Cerebellar vermis hypoplasia)
Incomplete hippocampal rotation — noted as an additional brain malformation. Suggested HPO: HP:0030050 (Abnormal hippocampus morphology, most specific available term)
Absent septum pellucidum — reported in a subset. Suggested HPO: HP:0030754 (Absent septum pellucidum, if available) or HP:0001300 (Cavum septum pellucidum, note as related structural anomaly)
Mirror movements — an axon-pathfinding/corticospinal-miswiring sign consistent with N-cadherin's role in axon guidance. Suggested HPO: HP:0007301 (Mirror movements of the hand) or HP:0002378 (Mirror movements)
Hypotonia (axial) with hypertonic extremities — mixed tone abnormality. Suggested HPO: HP:0001252 (Hypotonia), HP:0001276 (Hypertonia)
Cognitive/behavioral delay — variable severity, described qualitatively as "cognitive delays."

Ocular

Duane anomaly / Duane retraction syndrome — a specific ocular motility axon-pathfinding defect (cranial nerve VI miswiring), directly reflecting N-cadherin's axon-guidance role. Suggested HPO: HP:0009921 (Duane anomaly)
Peters anomaly — anterior-segment dysgenesis with corneal opacity/iridocorneal-lenticular adhesions, prominent in the PMID:31650526 cohort. Suggested HPO: HP:0007756 (Peters anomaly)
Other ocular anomalies collectively reported in ~11/13 evaluable individuals (exact sub-phenotypes not fully itemized in available abstracts beyond Duane anomaly and Peters anomaly).

Cardiac

Congenital cardiac anomalies — reported in ~9/13; left-sided cardiac lesions specifically noted in the Peters-anomaly cohort. Suggested HPO: HP:0001631 (Atrial septal defect), HP:0001629 (Ventricular septal defect) — specific lesion types not uniformly itemized across all published cases; "left-sided cardiac lesions" suggests possible left ventricular outflow tract anomalies. Broader term: HP:0001627 (Abnormal heart morphology)

Genital / Genitourinary

Cryptorchidism (males) — a recurring genital anomaly. Suggested HPO: HP:0000028 (Cryptorchidism)
Micropenis (males) — reported ("micropesis" in one source is a likely OCR error for "micropenis"). Suggested HPO: HP:0000054 (Micropenis)
Renal anomaly (ureteropelvic junction obstruction, UPJO) — reported in the first female patient (Kanjee et al. 2022, PMID:35708058), noted as the first genitourinary/renal finding described in a female with ACOGS, since prior reports documented only male-specific genital malformations. Suggested HPO: HP:0000072 (Hydronephrosis) / HP:0100957 (Ureteropelvic junction obstruction, if using UPJO-specific term)

Craniofacial dysmorphism

Hypertelorism (HP:0000316), flat nasal bridge (HP:0005280), low-set or posteriorly rotated ears (HP:0000369 / HP:0000368), upturned earlobes, thin upper lip (HP:0000219), small mouth with downturned corners (HP:0000175 / HP:0002714), low anterior hairline (HP:0000294).

Onset/severity/progression: All reported phenotypes are congenital/present from birth or early infancy (structural brain, cardiac, ocular, and genital malformations). Developmental delay becomes apparent in infancy/early childhood. The disorder does not appear to be progressive in the neurodegenerative sense — it is a static structural/developmental malformation syndrome, though longitudinal follow-up data are sparse given the small number of reported patients.

Quality of life impact: Not formally studied (no EQ-5D/SF-36 data identified); qualitatively, impact stems from intellectual disability, visual impairment (Duane anomaly, Peters anomaly with corneal opacity), and, when present, cardiac and renal complications requiring surgical/medical management.

4. Genetic / Molecular Information

Causal gene: CDH2 (cadherin 2, HGNC:1759, NCBI Gene 1000, OMIM 114020, chromosome 18q12.1), encoding N-cadherin (neuronal cadherin, cadherin-2)*, a classical type I transmembrane cadherin.

Variant classification and type: - Missense variants (majority; six of seven in the founding cohort cluster in EC4–EC5), frameshift variants, a splicing variant, and at least one nonsense variant (PMID:35708058) have been reported — spanning a broader range of variant classes than initially described. - ACMG/AMP classification: reported variants are generally classified pathogenic/likely pathogenic in ClinVar given de novo occurrence, absence from population databases, and functional evidence of impaired adhesion. - Allele frequency: Given all reported variants are de novo and disease-causing, they are essentially absent from gnomAD/population databases (consistent with severe, non-transmitted Mendelian disease); specific gnomAD allele counts were not available in the sources reviewed. - Origin: Exclusively germline, de novo (no somatic CDH2-ACOGS association reported).

Functional consequences: Rutherford/Accogli et al. demonstrated that "cells expressing these variants in the EC4-EC5 domains have a defect in cell-cell adhesion" (PMID:31585109) — i.e., the mechanism is loss of N-cadherin-mediated homophilic adhesion, acting in a dominant-negative and/or haploinsufficient manner. A separate report on ACOGS variants found that "de novo mutations in the CDH2 gene impair the cell adhesion function of N-cadherin by affecting self-binding as well as trans-binding with wildtype N-cadherin" — indicating a dominant-negative mechanism in which mutant protein interferes with wild-type N-cadherin function in trans, in addition to any haploinsufficiency.

Protein structure context: N-cadherin is composed of five extracellular cadherin (EC1–EC5) repeat domains (each ~110 amino acids), a transmembrane domain, and a cytoplasmic tail that binds β-catenin/p120-catenin linking to the actin cytoskeleton. Calcium ions bind at interdomain linker regions between EC repeats and rigidify the ectodomain into an extended rod required for trans-adhesion between apposing cell surfaces; EC1–EC2 mediate the primary trans-dimer "strand-swap" interaction, while EC4–EC5 (where most ACOG-syndrome variants cluster) contribute to maintaining the correct ectodomain length/rigidity required for productive trans-dimerization, and calcium-binding-site disruption at EC4–EC5 destabilizes this trans-adhesive interface.

Epigenetic information: No CDH2-ACOGS-specific epigenetic (DNA methylation/histone) data were identified in the literature reviewed.

Chromosomal abnormalities: ACOG syndrome is caused by point mutations/small indels, not by large chromosomal rearrangements; no recurrent CNV/deletion mechanism has been reported (distinguishing it from contiguous-gene 18q12 deletion syndromes, which are a different, unrelated entity).

Related but genetically/mechanistically distinct CDH2 disease associations (important for differential diagnosis and module design — these are separate CDH2 phenotypes, not part of ACOG syndrome per se): - Arrhythmogenic right ventricular cardiomyopathy (ARVC): CDH2 mutations were identified as a novel non-desmosomal genetic cause of ARVC (first reported in a South African family, 2017; PMID:28280076, Circ Cardiovasc Genet). This is an adult-onset, isolated cardiac arrhythmia/cardiomyopathy phenotype, mechanistically and clinically distinct from ACOG syndrome's developmental malformation presentation, though both stem from N-cadherin dysfunction (ARVC-associated variants are hypothesized to act primarily through desmosome/intercalated-disc destabilization in cardiomyocytes rather than broad developmental adhesion failure). - Dilated cardiomyopathy (DCM): A novel CDH2 variant has also been associated with DCM (PMC9468813, Front Med 2022). - Attention-Deficit/Hyperactivity Disorder 8: GeneCards lists CDH2 as associated with an ADHD susceptibility phenotype, distinct from full-syndrome ACOGS.

5. Environmental Information

No environmental factors, toxin exposures, lifestyle factors, or infectious agents have been implicated in CDH2-related ACOG syndrome — it is a purely genetic (de novo monogenic) disorder. No gene-environment interaction data exist.

6. Mechanism / Pathophysiology

Causal chain (from molecular lesion to clinical phenotype):

Molecular lesion: De novo heterozygous CDH2 variant (missense in EC4–EC5 calcium-binding sites, frameshift, nonsense, or splice-altering) →
Protein dysfunction: Impaired N-cadherin ectodomain rigidity/calcium coordination → defective homophilic trans-adhesion between N-cadherin molecules on apposing cell membranes, with evidence of a dominant-negative effect on wild-type N-cadherin trans-binding (not pure haploinsufficiency) →
Cellular process disruption: Failure of N-cadherin-dependent processes across multiple developing tissues — neuroepithelial integrity, radial glial scaffold confinement, growth-cone/axon-guidance receptor complex function, cardiomyocyte adherens-junction/intercalated-disc assembly, and periocular/anterior-segment mesenchymal-neural-crest adhesion →
Tissue-level consequence: Failure of commissural/callosal axons to cross the midline (agenesis/hypoplasia of the corpus callosum), miswiring of cranial motor axons (Duane anomaly), anterior-segment dysgenesis (Peters anomaly), cardiac septation/outflow anomalies, and disrupted genital tubercle/urogenital tract morphogenesis →
Organism-level phenotype: The multisystem ACOG syndrome presentation (global developmental delay/ID, callosal agenesis, axon-pathfinding defects, ocular anomalies, cardiac anomalies, genital anomalies, craniofacial dysmorphism).

Molecular pathways/cellular processes: N-cadherin functions at the head of a "cadherin–catenin–actin" adhesion complex: the cytoplasmic tail binds p120-catenin and β-catenin, which in turn links to α-catenin and the actin cytoskeleton, stabilizing adherens junctions and simultaneously modulating Wnt/β-catenin signaling availability. In neurons, N-cadherin also interacts with growth-cone guidance-receptor machinery relevant to netrin/DCC and other axon-pathfinding pathways (consistent with senior-author Frédéric Charron's expertise in axon guidance) and is implicated in growth-cone adhesion-dependent turning responses.

The 2022 review "Flying under the radar: CDH2 (N-cadherin), an important hub molecule in neurodevelopmental and neurodegenerative diseases" (Njoo & Charron lab collaborators, PMID:36213737, Front Neurosci 2022;16:972059) summarizes that during CNS development CDH2/N-cadherin is required for: "maintenance of neuroepithelial integrity, neural tube closure, confinement of radial glia progenitor cells to the ventricular zone and maintaining their proliferation-differentiation balance, postmitotic neural precursor migration, axon guidance, synaptic development and maintenance."

Cell types involved (suggested CL terms): - Neuroepithelial cells / radial glial cells (CL:0000681, radial glial cell) - Commissural/callosal projection neurons (CL:0000679, glutamatergic neuron; or CL:0011005, callosal neuron if available) - Cardiomyocytes (CL:0000746, cardiac muscle cell) - Cranial neural crest-derived mesenchyme (CL:0000333, migratory neural crest cell) — relevant to anterior-segment (Peters anomaly) and craniofacial dysmorphism - Growth cones of developing axons (structure rather than cell type; consider GO cellular component GO:0030426, growth cone)

Suggested GO Biological Process terms: - GO:0007156 (homophilic cell adhesion via plasma membrane adhesion molecules) - GO:0007411 (axon guidance) - GO:0021801 (cerebral cortex radial glia guided migration) / GO:0021795 (cerebral cortex cell migration) - GO:0007043 (cell-cell junction assembly) - GO:0060976 (coronary vasculature development) — less specific; better: GO:0003231 (cardiac ventricle development) or GO:0003179 (heart valve morphogenesis) depending on the specific cardiac lesion - GO:0021952 (central nervous system projection neuron axonogenesis) - GO:0060997 (dendritic spine morphogenesis) — for the synaptic maintenance role noted in the review

Suggested GO Cellular Component / Molecular Function terms: - GO:0005913 (cell-cell adherens junction) - GO:0098641 (cadherin binding involved in cell-cell adhesion) - GO:0008014 (obsolete/legacy) — prefer GO:0005509 (calcium ion binding) for the EC-domain calcium coordination function

Protein dysfunction mechanism: Predominantly dominant-negative — mutant N-cadherin monomers interfere with wild-type N-cadherin's ability to form productive trans-dimers at apposing cell surfaces ("affecting self-binding as well as trans-binding with wildtype N-cadherin"), rather than simple haploinsufficiency, though partial loss-of-function contribution cannot be excluded for frameshift/nonsense alleles predicted to trigger nonsense-mediated decay.

Immune system involvement: Not implicated; this is a developmental structural disorder, not an immune-mediated one.

Molecular profiling / omics: No transcriptomic, proteomic, metabolomic, or single-cell/spatial datasets specific to human CDH2-ACOG-syndrome patient tissue were identified in the literature reviewed; mechanistic data derive from in vitro cell-adhesion assays (e.g., aggregation assays in transfected cell lines) rather than patient-derived omics.

7. Anatomical Structures Affected

Organ level: - Primary: Brain (corpus callosum, cerebellar vermis, hippocampus, septum pellucidum), eyes (anterior segment/cornea, extraocular muscles/cranial nerve VI), heart, external/internal genitalia, kidneys/urinary tract. - Secondary: Craniofacial skeleton (dysmorphic features). - Body systems: Nervous system, cardiovascular system, ocular/visual system, genitourinary system, musculoskeletal/craniofacial system.

Suggested UBERON terms: - UBERON:0002336 (corpus callosum) - UBERON:0002037 (cerebellum) / UBERON:0002264 (cerebellar vermis, if available) - UBERON:0002421 (hippocampal formation) - UBERON:0000955 (brain) - UBERON:0000970 (eye) - UBERON:0000006 (islet of Langerhans — not relevant; disregard) — correct ocular term: UBERON:0000964 (cornea) for Peters anomaly; UBERON:0001776 (extraocular muscle) for Duane anomaly - UBERON:0000948 (heart) - UBERON:0000992 (gonad) / UBERON:0000473 (testis) for cryptorchidism; UBERON:0000030 (penis) for micropenis - UBERON:0002113 (kidney) / UBERON:0001222 (ureteropelvic junction, if available) for UPJO

Tissue/cell level: Neuroepithelium and radial glial scaffold of the ventricular zone; commissural axon tracts; cardiac myocardium and intercalated discs; corneal endothelium/anterior-segment mesenchyme (neural-crest derived).

Subcellular level (GO Cellular Component): Adherens junctions (GO:0005913), plasma membrane (site of N-cadherin's homophilic adhesive function), growth cone (GO:0030426).

Lateralization: No consistent lateralization pattern reported; corpus callosum agenesis is inherently a midline defect, and cardiac lesions described as "left-sided" in the Peters-anomaly cohort suggest some left-sided predilection for cardiac involvement specifically, but this is based on very small numbers.

8. Temporal Development

Onset: Congenital — all core structural anomalies (brain, cardiac, ocular, genital, craniofacial) are present from birth/prenatally, as expected for a developmental malformation syndrome. Developmental delay/intellectual disability becomes clinically apparent during infancy and early childhood as milestones are missed.

Onset pattern: Insidious recognition in infancy for the neurodevelopmental component; acute/immediately apparent at birth for structural anomalies (e.g., cardiac defects, genital anomalies, corneal opacity in Peters anomaly).

Progression: The disorder is best characterized as a static structural malformation syndrome rather than a progressive neurodegenerative one — no reports of regression or progressive deterioration were identified. However, given only ~15 patients have ever been reported and longitudinal follow-up is limited, the full natural history (e.g., adult outcomes, aging-related complications) remains poorly characterized.

Disease course pattern: Chronic, lifelong (congenital malformations and associated intellectual disability persist), not relapsing-remitting or episodic.

Critical periods: The pathophysiology implicates disruption during early embryonic/fetal development — specifically during neural tube closure, midline commissural axon crossing (corpus callosum formation, ~12–20 weeks gestation in humans), cardiac septation/looping (weeks 3–8 gestation), anterior-segment/ocular morphogenesis, and genital tubercle differentiation — all first-trimester-to-mid-second-trimester embryonic windows.

Remission: Not applicable — no remission pattern described for a congenital structural malformation syndrome.

9. Inheritance and Population

Epidemiology: Extremely rare — as of the most recent published case report (2022), "only 14 patients with ACOGS had been reported" prior to the fifteenth patient described by Kanjee et al. (PMID:35708058). No formal prevalence or incidence rate (cases per 100,000) has been established; the disorder is far below the threshold of most registry-based epidemiological reporting, consistent with its very recent (2019) delineation as a distinct syndrome and its de novo, non-transmitted genetic basis.

Inheritance pattern: Autosomal dominant, with essentially all reported cases arising from de novo variants (no vertical transmission reported to date, consistent with reduced reproductive fitness typical of severe multisystem developmental syndromes).

Penetrance: Presumed high/complete for the core neurodevelopmental and structural phenotype, though formal penetrance estimates are not available given the small cohort and absence of inherited (non-de-novo) transmission data.

Expressivity: Notably variable — patients show a spectrum from ACOG-syndrome-predominant (axon-pathfinding/callosal-predominant) to Peters-anomaly-predominant (anterior-segment ocular-predominant) presentations, and individual features (cardiac, genital, renal) are present in only a subset of patients (e.g., renal/UPJO reported in only one patient to date). This variable expressivity may partly correlate with variant location/type but sample sizes are too small for firm genotype-phenotype rules.

Genetic anticipation: Not applicable/not reported (not a repeat-expansion disorder).

Germline mosaicism: Not specifically documented in the literature reviewed, though it remains a theoretical possibility relevant to recurrence-risk counseling for parents of an affected child, as with other de novo dominant disorders.

Founder effects: None reported; cases have been identified across North America, Europe, and Turkey (Kanjee et al., first reported case from Turkey), consistent with pan-ethnic occurrence and no population-specific founder variant.

Consanguinity: Not implicated — consistent with the de novo dominant mechanism (consanguinity is relevant to recessive disease, not de novo dominant disease).

Carrier frequency: Not applicable for a de novo dominant, non-carrier-based condition.

Population demographics: - Sex ratio: Both males and females affected; genital anomalies (cryptorchidism, micropenis) were initially described only in males, but Kanjee et al. (2022) reported "the first female patient" with ACOGS, presenting instead with a renal anomaly (UPJO), suggesting genitourinary tract involvement in females manifests differently (upper urinary tract rather than external genitalia). - Geographic distribution: Cases reported from North America, Europe, and Turkey; no endemic or regionally clustered pattern identified — consistent with a pan-ethnic de novo disorder. - Age distribution: All reported cases are pediatric at time of publication (diagnosis in infancy/childhood); no adult natural-history cohort has been published.

10. Diagnostics

Clinical/laboratory tests: No CDH2-ACOGS-specific biochemical biomarker exists; diagnosis relies on recognition of the clinical/imaging phenotype plus molecular confirmation.

Imaging studies: - Brain MRI: Essential for detecting agenesis/hypoplasia of the corpus callosum, cerebellar vermis hypoplasia, incomplete hippocampal rotation, and absent septum pellucidum. - Echocardiography: For detection of congenital cardiac anomalies (including left-sided lesions). - Renal/abdominal ultrasound: For detection of urinary tract anomalies (e.g., UPJO/hydronephrosis), as illustrated by the female patient reported by Kanjee et al. - Ophthalmologic exam (slit-lamp, anterior-segment imaging): For Duane anomaly and Peters anomaly detection.

Genetic testing: - Recommended approach: Given the phenotypic overlap with numerous other syndromic corpus callosum agenesis/neurodevelopmental disorders, exome sequencing (WES) or genome sequencing (WGS), typically as a trio (proband + both parents) to establish de novo status, is the diagnostic approach used in all reported cases (the founding cohort was largely ascertained through the NIH Undiagnosed Diseases Network and international WES/WGS collaborations). - Gene panels: CDH2 is increasingly included on clinical "corpus callosum agenesis," "intellectual disability," and "malformations of cortical development" gene panels (e.g., Genomics England PanelApp lists CDH2 under "Malformations of cortical development" and "Paediatric disorders — additional genes" panels). - Single-gene testing: Feasible once a specific familial variant is known, but as a first-tier test is unlikely to be efficient given phenotypic overlap with many other genes. - Chromosomal microarray (CMA)/karyotyping: Not diagnostic for CDH2 point variants but often performed first-line to exclude copy-number/chromosomal causes of corpus callosum agenesis or multiple congenital anomalies before sequencing.

Clinical/diagnostic criteria: No formal consensus diagnostic criteria (e.g., DSM/ICD-style) have been published; diagnosis is currently based on the combination of (1) characteristic multisystem phenotype (callosal/axon-pathfinding + ocular + cardiac + genital + craniofacial dysmorphism) and (2) identification of a de novo heterozygous CDH2 variant.

Differential diagnosis: Other syndromic corpus callosum agenesis disorders (e.g., Mowat-Wilson syndrome, Acrocallosal syndrome, other Duane-anomaly-associated syndromes such as Okihiro/Duane-radial ray syndrome [SALL4], and other cadherin/catenin-pathway disorders), isolated Peters anomaly (PAX6, PITX2, FOXC1, CYP1B1, COL6A3, B3GLCT, DOP1B and other genes), and other causes of syndromic developmental delay with cardiac and genital anomalies (e.g., CHARGE syndrome, VACTERL association).

Screening: No population-based or newborn screening applicable — the disorder is not detectable by standard biochemical newborn screening panels and is far too rare for targeted population screening; diagnosis occurs reactively based on clinical presentation.

11. Outcome / Prognosis

Survival/mortality: No mortality data specific to CDH2-ACOGS were identified; the disorder has not been reported as inherently life-limiting, though outcomes will depend heavily on the severity of associated cardiac and renal anomalies in individual patients, which can independently carry morbidity/mortality risk if uncorrected.

Morbidity/function: Long-term functional outcomes are not well characterized given the small number of reported, largely pediatric, cases. Anticipated morbidity domains include: cognitive/intellectual disability (variable, generally mild-to-moderate based on available descriptions), visual impairment (from Peters anomaly's corneal opacity and/or Duane anomaly's motility restriction), and any sequelae of unrepaired/repaired structural cardiac or renal anomalies.

Complications: Congenital cardiac lesions and renal/urinary tract anomalies (e.g., UPJO leading to hydronephrosis) may require surgical intervention and carry their own complication profiles independent of the neurodevelopmental features.

Recovery potential: Structural malformations (cardiac, renal, ocular) may be amenable to surgical correction with resulting improvement in organ-specific function; the neurodevelopmental/intellectual disability component is not expected to "recover" but may improve functionally with early intervention (standard practice for developmental delay, not disease-specific).

Prognostic factors: Not formally established; qualitatively, the presence and severity of cardiac and renal anomalies, and the degree of corpus callosum abnormality/associated brain malformation burden, would be expected to influence overall prognosis, but no quantitative prognostic model exists given the rarity of the condition.

12. Treatment

There is no disease-modifying or CDH2-targeted therapy for ACOG syndrome; management is entirely symptomatic, supportive, and multidisciplinary, following standard-of-care approaches for each organ-system manifestation (this mirrors management of other syndromic multiple-congenital-anomaly/intellectual disability disorders where no gene-specific therapy exists).

Suggested multidisciplinary management approach (NCIT terms in parentheses where applicable): - Neurodevelopmental/rehabilitative: Early intervention services, physical therapy (NCIT:C15302), occupational therapy (NCIT:C121351), speech-language therapy (NCIT:C159273), special education support for intellectual disability. - Ophthalmologic: Surgical management of Peters anomaly (e.g., penetrating keratoplasty for corneal opacity in severe cases) (NCIT:C15329, Surgical Procedure); strabismus/Duane anomaly management may include observation or extraocular muscle surgery depending on severity and functional impact. - Cardiac: Standard congenital heart disease management per lesion type — may range from surveillance to surgical repair (NCIT:C15329, Surgical Procedure; cardiology follow-up). - Genitourinary: Urologic evaluation/management of cryptorchidism (orchiopexy) and UPJO (pyeloplasty if obstructive/symptomatic) (NCIT:C15329, Surgical Procedure). - Genetic counseling: Recommended for all families given the de novo autosomal dominant mechanism, to discuss low (but non-zero, due to theoretical germline mosaicism) recurrence risk for future pregnancies and to facilitate cascade/predictive considerations (NCIT:C15240, Genetic Counseling). - Supportive care: Routine surveillance/supportive care coordinated across specialists (NCIT:C15747, Supportive Care).

Experimental treatments: No CDH2-ACOGS-specific clinical trials (ClinicalTrials.gov) were identified — the extreme rarity of the condition (~15 reported patients) makes disease-specific trials unlikely at this stage. No gene therapy, RNA-based therapy, or targeted molecular therapy has been proposed or is in development for this disorder in the literature reviewed.

Treatment outcomes: No systematic data on treatment response rates or adverse events specific to this population exist, again reflecting the very small published cohort.

13. Prevention

Primary prevention: Not applicable in a conventional sense — the disorder results from de novo germline mutation with no known modifiable environmental trigger, so there are no primary-prevention (risk-factor-modification) strategies.

Secondary prevention / screening: No population or targeted screening program exists or would be practical given the extreme rarity and de novo nature of the disorder. Prenatal detection is theoretically possible via detailed fetal anatomy ultrasound (identifying corpus callosum agenesis, cardiac anomalies, or genital anomalies) followed by diagnostic prenatal exome sequencing if a syndromic picture is suspected, but this is not a formal screening recommendation specific to CDH2.

Genetic counseling: The main "preventive" intervention available is reproductive genetic counseling for parents of an affected child — given de novo dominant inheritance, recurrence risk for future pregnancies is low but not zero (accounting for theoretical parental germline mosaicism, as is standard counseling practice for de novo dominant conditions); prenatal diagnosis via chorionic villus sampling/amniocentesis with targeted variant testing would be available once the familial pathogenic variant is known.

Public health interventions: None specific to this ultra-rare monogenic disorder.

14. Other Species / Natural Disease

Taxonomy: No naturally occurring CDH2-ACOG-syndrome-like disease has been reported in non-human species (e.g., in OMIA, the animal-disease counterpart of OMIM). CDH2/N-cadherin is highly evolutionarily conserved across vertebrates (relevant orthologs exist in mouse, zebrafish, chick, Xenopus), but no spontaneous veterinary case series analogous to human ACOG syndrome was identified.

Orthologous gene: Mouse Cdh2 (MGI:88355), located on a syntenic region; extensively studied in developmental biology (see Model Organisms, below).

Comparative biology: N-cadherin's role in neural tube closure, cardiac morphogenesis, and axon guidance is deeply conserved across vertebrate models, supporting strong mechanistic plausibility that mouse/zebrafish CDH2 loss-of-function models recapitulate aspects of the human phenotype, even though a naturally occurring animal ACOG-syndrome phenocopy has not been documented.

Zoonotic potential: Not applicable (non-infectious, genetic disorder).

15. Model Organisms

Mouse (Mus musculus, Cdh2, MGI:88355): - Constitutive knockout: Global Cdh2-null mice are embryonic lethal around E10, due to severe cardiac developmental defects. Reported abnormalities include growth retardation, an enlarged/malformed heart, distended pericardial sac, abnormal heart tube looping, a "wavy" (undulated) neural tube, irregular somite shape, and abnormal embryonic turning — precluding assessment of later CNS developmental roles in the constitutive knockout (JAX strain 003179). - Conditional/cardiac-specific knockout: Because global knockout is embryonic lethal via cardiac failure, cardiac-specific conditional deletion strategies have been used. Non-inducible cardiomyocyte-specific deletion (αMHC-Cre) is also embryonic lethal; an inducible cardiac-specific Cre was required to bypass the embryonic requirement. Inducible postnatal cardiomyocyte-specific Cdh2 deletion "disrupts cell-cell adherens contacts and destabilization of gap junctions, resulting in conduction defects, spontaneous ventricular arrhythmias, cardiomyopathy, and premature cardiac death" (relevant to the CDH2-ARVC/DCM cardiac phenotypes specifically, and mechanistically informative for the cardiac component of ACOG syndrome). - Neural-specific conditional models: Conditional CNS deletion approaches (e.g., using neural-lineage Cre drivers) have been used in the broader N-cadherin literature to study neuroepithelial integrity, neural tube closure, radial glial scaffold maintenance, and axon guidance — consistent with, and mechanistically supportive of, the CNS phenotypes (corpus callosum agenesis, axon-pathfinding defects) seen in human ACOG syndrome patients, per the review by PMID:36213737.

Zebrafish and other model systems: N-cadherin (cdh2) mutant/morphant zebrafish have long been used to study neural tube and heart-tube morphogenesis given the same fundamental conservation of N-cadherin function, though a study specifically modeling the human ACOG-syndrome missense alleles in zebrafish was not identified in the sources reviewed.

In vitro/cell-based models: The primary functional validation for human ACOG-syndrome-associated CDH2 variants to date has been cell-based adhesion/aggregation assays in transfected cell lines (e.g., L-cells or similar cadherin-null lines classically used for cadherin adhesion assays), which demonstrated that EC4–EC5 domain variants impair both self-binding (cis) and trans-binding to wild-type N-cadherin, supporting a dominant-negative mechanism (PMID:31585109).

Model limitations: The constitutive mouse knockout's early embryonic lethality (E10, via cardiac failure) means it cannot recapitulate — or be used to directly study — the later CNS callosal/axon-pathfinding phenotypes central to the human syndrome; conditional/tissue-specific and patient-variant-knock-in mouse models (rather than null alleles) would be needed to more faithfully model the human missense/dominant-negative disease mechanism, and such variant-specific knock-in models were not identified as yet published in the literature reviewed.

Summary Table of Key Ontology Term Suggestions

Table (click to expand)

Category	Suggested Term	ID
Disease	Agenesis of corpus callosum, cardiac, ocular, and genital syndrome	OMIM:618929 / MONDO:0030065
Gene	CDH2	HGNC:1759 / NCBI Gene:1000
Phenotype	Agenesis of corpus callosum	HP:0001274
Phenotype	Duane anomaly	HP:0009921
Phenotype	Peters anomaly	HP:0007756
Phenotype	Global developmental delay	HP:0001263
Phenotype	Cryptorchidism	HP:0000028
Phenotype	Micropenis	HP:0000054
Phenotype	Cerebellar vermis hypoplasia	HP:0001320
Biological process	Homophilic cell adhesion via plasma membrane adhesion molecules	GO:0007156
Biological process	Axon guidance	GO:0007411
Cellular component	Cell-cell adherens junction	GO:0005913
Cell type	Radial glial cell	CL:0000681
Cell type	Cardiac muscle cell	CL:0000746
Anatomy	Corpus callosum	UBERON:0002336
Anatomy	Heart	UBERON:0000948

Notes on Evidence Gaps

Prevalence/incidence: No formal population-level rate is available (only cumulative case counts, ~15 patients as of 2022); any later-reported cases beyond the sources reviewed here should be checked via a fresh PubMed search before curation, given the field is actively expanding one case report at a time.
ORPHA number: A dedicated Orphanet entry number specifically for "ACOG syndrome"/ACOGS was not conclusively located in this search (Orphanet does maintain a CDH2 gene page linking to associated rare diseases); this should be verified directly against Orphanet's live database before finalizing a KB entry.
Quantitative phenotype frequencies beyond the qualitative fractions cited (e.g., "10/12," "11/13," "9/13") should be re-verified against the primary AJHG and Clinical Genetics papers' full tables, as only abstract/secondary-source-level detail was accessible in this research pass.
No dedicated GeneReviews chapter for CDH2-ACOG syndrome was identified as of this search — the primary clinical reference remains the original 2019 AJHG paper and subsequent case reports.